Literature DB >> 10408496

Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders.

C M Pariante, M G Orrù, A Baita, M G Farci, B Carpiniello.   

Abstract

We prospectively studied 50 patients treated with interferon-alpha for chronic hepatitis and found no evidence that patients with a pre-existing mood or anxiety disorder were more likely than other patients to interrupt the interferon-alpha therapy.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10408496     DOI： 10.1016/S0140-6736(98)04793-X

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  25 in total

1.  Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

Authors:  B R Edlin; K H Seal; J Lorvick; A H Kral; D H Ciccarone; L D Moore; B Lo
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

2.  Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression.

Authors:  Jennifer C Felger; Oyetunde Alagbe; Fang Hu; Deborah Mook; Amanda A Freeman; Mar M Sanchez; Ned H Kalin; Emiliangelo Ratti; Charles B Nemeroff; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2007-08-02       Impact factor: 13.382

3.  Major depressive disorder in hepatitis C: an open-label trial of escitalopram.

Authors:  Ondria C Gleason; William R Yates; Michelle A Philipsen
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

4.  What can post-mortem studies tell us about the pathoetiology of suicide?

Authors:  Ghanshyam N Pandey; Yogesh Dwivedi
Journal:  Future Neurol       Date:  2010-09

Review 5.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

6.  Psychiatric and substance use disorders among methadone maintenance patients with chronic hepatitis C infection: effects on eligibility for hepatitis C treatment.

Authors:  Steven L Batki; Kelly M Canfield; Robert Ploutz-Snyder
Journal:  Am J Addict       Date:  2011-05-31

7.  Feasibility and impact of a guided symptom exposure augmented cognitive behavior therapy protocol to prevent symptoms of pharmacologically induced depression: A pilot study.

Authors:  Lata K McGinn; Anna Van Meter; Ian Kronish; Jessica Gashin; Karen Burns; Natalie Kil; Thomas G McGinn
Journal:  Cognit Ther Res       Date:  2019-02-12

Review 8.  Trained innate immunity: a salient factor in the pathogenesis of neuroimmune psychiatric disorders.

Authors:  A P Salam; A Borsini; P A Zunszain
Journal:  Mol Psychiatry       Date:  2017-12-12       Impact factor: 15.992

9.  Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment.

Authors:  S J Bull; P Huezo-Diaz; E B Binder; J F Cubells; G Ranjith; C Maddock; C Miyazaki; N Alexander; M Hotopf; A J Cleare; S Norris; E Cassidy; K J Aitchison; A H Miller; C M Pariante
Journal:  Mol Psychiatry       Date:  2008-05-06       Impact factor: 15.992

10.  Hepatitis C for addiction professionals.

Authors:  Diana Sylvestre
Journal:  Addict Sci Clin Pract       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.